Ortho Dermatologics

Ortho Dermatologics Duobrii Approved For Plaque Psoriasis In Adults

FDA Approves New Psoriasis Treatment

The U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Ortho Dermatologics’ DUOBRII (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults. The company expects the topical lotion, which is the first and only topical that contains a unique combination of halobetasol propionate and tazarotene in one formulation, to be commercially available in June 2019.

Ortho Dermatologics Accepting Applications for its Aspire Higher Scholarship Program

Ortho Dermatologics is now accepting applications for its 2019 Aspire Higher scholarship program, which will award $90,000 total to nine students who have been treated for a dermatologic condition.

To apply for the scholarship, students are required to share an essay about their experience of living with a dermatologic condition, as well as the role that a dermatologist, physician assistant or nurse practitioner played in helping treat them.

Ortho Dermatologics Announces Aspire Scholarship Recipients

Ortho Dermatologics, a division of Bausch Health Companies, has announced the 2018 honorees of its Aspire Higher program, which since 2013 has granted more than $450,000 in scholarships to students who have been affected by dermatologic conditions. This year nine students will receive scholarships of $10,000 each to pursue graduate or undergraduate degrees at an accredited, nonprofit, two- or four-year college, university, or advanced (post-high school) vocational or technical school.

Valeant Dermatology Is Now Ortho Dermatologics

Humphries Announces Rebranding to Ortho Dermatologics

Valeant is rebranding its dermatology products under the name Ortho Dermatologics, which was acquired by Valeant in 2011. The rebranding coincides with the company’s launch of SILIQ, a biologic drug approved for the treatment of psoriasis. “The branding under Ortho Dermatologics allows us to showcase what we have as a company,” says William (Bill) Humphries, executive vice president of dermatology at Valeant. “We have more than 100 years of dermatology experience on the team now and we have a portfolio of dermatology products that, I think, is unrivaled in the industry.”